Genes and hypertension

Current Pharmaceutical Design

Volumn 9, Issue 21, 2003, Pages 1679-1689

  Garcia, E A ^a   Newhouse, S ^a   Caulfield, M J ^a   Munroe, P B ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adducin; Blood pressure; Essential hypertension; Micro arrays; Pharmacogenetics; Renin angiotensin system; Single nucleotide polymorphisms; WNK kinases

Indexed keywords

17BETA (3 FURYL) 5BETA ANDROSTANE 3BETA,14BETA,17ALPHA TRIOL; ADDUCIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; COTRANSPORTER; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; MINERALOCORTICOID ANTAGONIST; PHOSPHOTRANSFERASE; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; COMPARATIVE GENE MAPPING; DIURETIC ACTIVITY; DNA MICROARRAY; DRUG RESPONSE; GENE DELETION; GENETIC LINKAGE; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HYPERTENSION; MISSENSE MUTATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOHYPOALDOSTERONISM; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ANDROSTANOLS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALMODULIN-BINDING PROTEINS; CARBOXYPEPTIDASES; GENOMICS; HUMANS; HYPERTENSION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS; PROTEIN-SERINE-THREONINE KINASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 0041989748     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454513     Document Type: Review

References (78)

1. Grimm RH Jr, Cohen JD, Smith WM, Falvo-Gerard L, Neaton JD. Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups. Arch Int Med 1985; 145: 1191-9
2. Domanski M, Mitchell G, Pfeffer M, Neaton JD, Norman J, Svendsen K, et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002; 287: 2677-83
3. Anonymous. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Int Med 1997; 157: 2413-46
4. Oparil S, Weber MA. Hypertension : A companion to Brenner & Rector's The kidney. 2000, Philadelphia: W.B. Saunders. XXII, 757.
5. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 293: 1107-12.
6. Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, Cobb MH. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J Biol Chem 2000; 275: 16795-801.
7. Verissimo F, Jordan P. WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene 2001; 20: 5562-9.
8. Choate KA, Kahle KT, Wilson FH, Nelson-Williams C, Lifton RP. WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse C1- - transporting epithelia. Proc Natl Acad Sci U S A 2003; 100: 663-8.
9. Mayan H, Vered I, Mouallem M, Tzadok-Witkon M, Pauzner R, Farfel Z. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 2002; 87: 3248-54.
10. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, et al. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A 2003; 100: 680-4.
11. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9.
12. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-43.
13. Zhang H, Wada J, Hida K, Tsuchiyama Y, Hiragushi K, Shikata K, et al. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J Biol Chem 2001; 276: 17132-9.
14. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002; 23: 177-83.
15. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-8.
16. Boehm M, Nabel EG. Angiotensin-converting enzyme 2 - a new cardiac regulator. N Engl J Med 2002; 347: 1795-7.
17. Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, et al. Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc 2002; 124: 11852-3.
18. Manunta P, Barlassina C, Bianchi G. Adducin in essential hypertension. FEBS Lett 1998; 430: 41-4.
19. Salardi S, Saccardo B, Borsani G, Modica R, Ferrandi M, Tripodi MG, et al. Erythrocyte adducin differential properties in the normotensive and hypertensive rats of the Milan strain. Characterization of spleen adducin m-RNA. Am J Hypertens 1989; 2: 229-37.
20. Bianchi G, Baer PG, Fox U, Duzzi L, Pagetti D, Giovannetti AM. Changes in renin, water balance, and sodium balance during development of high blood pressure in genetically hypertensive rats. Circ Res 1975; 36: 153-61.
21. Bianchi G, Tripodi G, Casari G, Salardi S, Barber BR, Garcia R, et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc Natl Acad Sci U S A 1994; 91: 3999-4003.
22. Casari G, Barlassina C, Cusi D, Zagato L, Muirhead R, Righetti M, et al. Association of the alpha-adducin locus with essential hypertension. Hypertension 1995; 25: 320-6.
23. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997; 349: 1353-7.
24. Castellano M, Barlassina C, Muiesan ML, Beschi M, Cinelli A, Rossi F, et al. Alpha-adducin gene polymorphism and cardiovascular phenotypes in a general population. J Hypertens 1997; 15: 1707-10.
25. Iwai N, Tamaki S, Nakamura Y, Kinoshita M. Polymorphism of alpha-adducin and hypertension. Lancet 1997; 350:369.
26. He X, Zhu DL, Chu SL, Jin L, Xiong MM, Wang GL, et al. alpha-Adducin gene and essential hypertension in China. Clin Exp Hypertens 2001; 23: 579-89.
27. Melander O, Bengtsson K, Orho-Melander M, Lindblad U, Forsblom C, Rastam L, et al. Role of the Gly460Trp polymorphism of the alpha-adducin gene in primary hypertension in Scandinavians. J Hum Hypertens 2000; 14: 43-6.
28. Clark CJ, Davies E, Anderson NH, Farmer R, Friel EC, Fraser R, et al. alpha-adducin and angiotensin I-converting enzyme polymorphisms in essential hypertension. Hypertension 2000; 36: 990-4.
29. Manunta P, Burnier M, D'Amico M, Buzzi L, Maillard M, Barlassina C, et al. Adducin polymorphism affects renal proximal tubule reabsorption in hypertension. Hypertension 1999; 33: 694-7.
30. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, Ferrari P. Ouabain-like factor quantification in mammalian tissues and plasma: comparison of two independent assays. Hypertension 1997; 30: 886-96.
31. Ferrari P, Ferrandi M, Tripodi G, Torielli L, Padoani G, Minotti E, et al. PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. J Pharmacol Exp Ther 1999; 288: 1074-83.
32. Ferrandi M, Barassi P, Minotti E, Duzzi L, Molinari I, Bianchi G, et al. PST 2238: a new antihypertensive compound that modulates renal Na-K pump function without diuretic activity in Milan hypertensive rats. J Cardiovasc Pharmacol 2002; 40: 881-9.
33. Doris PA. Ouabain in plasma from spontaneously hypertensive rats. Am J Physiol 1994; 266: H360-4.
34. Nguyen AT, Hayward-Lester A, Sabatini S, Doris PA. Renal Na+, K+-ATPase in SHR: studies of activity and gene expression. Clin Exp Hypertens 1998; 20: 641-56.
35. Ishikawa K, Katsuya T, Sato N, Nakata Y, Takami S, Takiuchi S, et al. No association between alpha-adducin 460 polymorphism and essential hypertension in a Japanese population. Am J Hypertens 1998; 11: 502-6.
36. Barlassina C, Norton GR, Samani NJ, Woodwiss AJ, Candy GC, Radevski I, et al. Alpha-adducin polymorphism in hypertensives of South African ancestry. Am J Hypertens 2000; 13: 719-23.
37. Melander O, Bengtsson K, Orho-Melander M, Lindblad U, Forsblom C, Rastam L, et al. Role of the Gly460Trp polymorphism of the alpha-adducin gene in primary hypertension in Scandinavians. J Hum Hypertens 2000; 14: 43-6.
38. Angius A, Petretto E, Maestrale GB, Forabosco P, Casu G, Piras D, et al. A new essential hypertension susceptibility locus on chromosome 2p24-p25, detected by genomewide search. Am J Hum Genet 2002; 71: 893-905.
39. Allayee H, de Bruin TW, Michelle Dominguez K, Cheng LS, Ipp E, Cantor RM, et al. Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p. Hypertension 2001; 38: 773 -8.
40. Kristjansson K, Manolescu A, Kristinsson A, Hardarson T, Knudsen H, Ingason S, et al. Linkage of essential hypertension to chromosome 18q. Hypertension 2002; 39: 1044-9.
41. Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension 2000; 36: 477-83.
42. Cooper RS, Luke A, Zhu X, Kan D, Adeyemo A, Rotimi C, et al. Genome scan among Nigerians linking blood pressure to chromosomes 2, 3, and 19. Hypertension 2002; 40: 629-33.
43. Xu X, Rogus JJ, Terwedow HA, Yang J, Wang Z, Chen C, et al. An extreme-sib-pair genome scan for genes regulating blood pressure. Am J Hum Genet 1999; 64: 1694-701.
44. Rao DC, Province MA, Leppert MF, Oberman Al, Heiss G, Ellison RC, et al. A genome-wide affected sibpair linkage analysis of hypertension: the HyperGEN network. Am J Hypertens 2003; 16: 148-150
45. Rice T, Rankinen T, Province MA, Chagnon YC, Perusse L, Borecki IB, et al. Genome-wide linkage analysis of systolic and diastolic blood pressure: the Quebec Family Study. Circulation 2000; 102: 1956-63.
46. Rice T, Rankinen T, Chagnon YC, Province MA, Perusse L, Leon AS, et al. Genomewide linkage scan of resting blood pressure: HERITAGE Family Study. Health, Risk Factors, Exercise Training, and Genetics. Hypertension 2002; 39: 1037-43.
47. Krushkal J, Ferrell R, Mockrin SC, Turner ST, Sing CF, Boerwinkle E. Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings. Circulation 1999; 99: 1407-10.
48. Baima J, Nicolaou M, Schwartz F, DeStefano AL, Manolis A, Gavras I, et al. Evidence for linkage between essential hypertension and a putative locus on human chromosome 17. Hypertension 1999; 34: 4-7.
49. Julier C, Delepine M, Keavney B, Terwilliger J, Davis S, Weeks DE, et al. Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure linkage on rat chromosome 10. Hum Mol Genet 1997; 6: 2077-85.
50. Kardia SLR, Rozek LS, Krushkal J, Ferrell RE, Turner ST, Hutchinson R, et al. Genome-wide linkage analyses for hypertension genes in two ethnically and geographically diverse populations. Am J Hypertens 2003; 16: 154-157.
51. Ranade K, Hsuing AC, Wu KD, Chang MS, Chen YT, Hebert J, et al. Lack of evidence for an association between alpha-adducin and blood pressure regulation in Asian populations. Am J Hypertens 2000; 13: 704-9.
52. Ranade K, Hinds D, Hsiung CA, Chuang L-M, Chang M-S, Chen Y-T, et al. a genome scan for hypertension susceptibility loci in populations of Chinese and Japanese origins. Am J Hypertens 2003; 16: 158-162.
53. Thiel BA, Chakravarti A, Cooper RS, Luke A, Lewis S, Lynn A, et al. A Genome-Wide Linkage Analysis Investigating the Determinants of Blood Pressure in Whites and African Americans. Am J Hypertens 2003; 16: 151-153.
54. The FBBP investigators. Multi-Center Genetic Study of Hypertension: The Family Blood Pressure Program (FBPP). Hypertension. 2002. 39: 3-9.
55. Province MA, Arnett DK, Hunt SC, Leiendecker-Foster C, Eckfeldt JH, Oberman A, et al. Association between the alpha-adducin gene and hypertension in the HyperGEN Study. Am J Hypertens 2000; 13: 710-8.
56. Arngrimsson R, Sigurardttir S, Frigge ML, Bjarnad ttir RI, Jonsson T, Stefansson H, et al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet 1999; 8: 1799-805.
57. Moses EK, Lade JA, Guo G, Wilton AN, Grehan M, Freed K, et al. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet 2000; 67: 1581-5.
58. Laivuori H, Lahermo P, Ollikainen V, Widen E, Haiva-Mallinen L, Sundstrom H, et al. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet 2003; 72: 168-77.
59. Lalouel JM, Rohrwasser A. Development of genetic hypotheses in essential hypertension. J Hum Genet 2001; 46: 299-306.
60. Samani NJ. Genome scans for hypertension and blood pressure regulation. Am J Hypertens 2003; 16: 167-71.
61. Chiu AG, Krowiak EJ, Deeb ZE. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology. Laryngoscope 2001; 111: 1729-31.
62. Glorioso N, Manunta P, Filigheddu F, Troffa C, Stella P, Barlassina C, et al. The role of alpha-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999; 34: 649-54.
63. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37: 739-43.
64. Okuda T, Sumiya T, Mizutani K, Tago N, Miyata T, Tanabe T, et al. Analyses of differential gene expression in genetic hypertensive rats by microarray. Hypertens Res 2002; 25: 249-55.
65. Okuda T, Sumiya T, Iwai N, Miyata T. Difference of gene expression profiles in spontaneous hypertensive rats and Wistar-Kyoto rats from two sources. Biochem Biophys Res Commun 2002; 296: 537-43.
66. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 2000; 275: 40504-10.
67. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 2003; 13: 7-17.
68. Perola M, Kainulainen K, Pajukanta P, Terwilliger JD, Hiekkalinna T, Ellonen P, et al. Genome-wide scan of predisposing loci for increased diastolic blood pressure in Finnish siblings. J Hypertens 2000; 18: 1579-85.
69. Sharma P, Fatibene J, Ferraro F, Jia H, Monteith S, Brown C, et al. A genome-wide search for susceptibility loci to human essential hypertension. Hypertension 2000; 35: 1291-6.
70. Pankow JS, Rose KM, Oberman A, Hunt SC, Atwood LD, Djousse L, et al. Possible locus on chromosome 18q influencing postural systolic blood pressure changes. Hypertension 2000; 36: 471-6.
71. Atwood LD, Samollow PB, Hixson JE, Stern MP, MacCluer JW. Genome-wide linkage analysis of pulse pressure in Mexican Americans. Hypertension 2001; 37: 425-8.
72. Zhu DL, Wang HY, Xiong MM, He X, Chu SL, Jin L, et al. Linkage of hypertension to chromosome 2q14-q23 in Chinese families. J Hypertens 2001; 19: 55-61.
73. Hsueh WC, Mitchell BD, Schneider JL, Wagner MJ, Bell CJ, Nanthakumar E, et al. QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31-34 in Old Order Amish. Circulation 2000; 101: 2810-6.
74. Harrap SB, Wong ZY, Stebbing M, Lamantia A, Bahlo M. Blood pressure QTLs identified by genome-wide linkage analysis and dependence on associated phenotypes. Physiol Genomics 2002; 8: 99-105.
75. Hunt SC, Ellison RC, Atwood LD, Pankow JS, Province MA, Leppert MF. Genome scans for blood pressure and hypertension: the National Heart, Lung, and Blood Institute Family Heart Study. Hypertension 2002; 40: 1-6.
76. Danielsson BR, Skold AC, Azarbayjani F. Class III antiarrhythmics and phenytoin: teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr Pharm Des 2001; 7(9): 787-802.
77. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Des 2002; 8(3): 155-66.
78. Wouters J, Ooms F. Small molecule crystallography in drug design. Curr Pharm Des 2001; 7(7): 529-45.